Heart pump may help High-Risk patients get Life-Saving artery treatment

NCT ID NCT07678021

Not yet recruiting Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether using a temporary heart pump (CorVad) during a procedure to open blocked arteries (PCI) can improve outcomes for people with complex coronary artery disease and a very weak heart (ejection fraction below 35%). Half of the 452 participants will receive the pump-assisted PCI plus standard medications, while the other half will receive medications alone. The main goal is to see if the pump reduces major heart and brain events like death, heart attack, stroke, or heart failure readmission over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CorVad micro-axial flow pump (device) and optimal medical therapy (drugs)
What this could lead to: If successful, this approach could offer a safer way to open blocked arteries in people with severely weakened hearts, potentially reducing heart attacks, strokes, and hospitalizations.
What could go wrong: This is a mid-stage trial with 452 participants, so results may not apply to everyone. The pump procedure carries risks like bleeding, hemolysis, or stent complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder left ventricular failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE (CAD)

Contacts and locations

Locations

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.